Introduction
Adrenergic stimulant drugs are much used to reverse or diminish the w'idespread small airway obstruction which characterizes attacks of bronchial asthma. Until recently the drug most often used for this was isoprenaline given by aerosol inhalation. Isoprenaline has a comparatively short bronchodilator action because it is rapidly metabolized by the enzyme catechol-o-methyl transferase. Moreover, in addition to being a powerful stimulator of f32-adrenergic receptors leading to bronchodilation it also stimulates #,/-receptors in the myocardium, leading to tachycardia and a rise in cardiac output (Aviado and Schmidt, 1957; Kelman et al., 1969) . Probably as a direct result of the cardiac effects hypoxaemia may become worse after isoprenaline even though airway obstruction is diminished, and where large doses are given, particularly when the patient is hypoxaemic, serious cardiac complications such as ventricular fibrillation or ventricular asystole may occur. The recent rise and decline in asthma mortality coincided with the widespread use of portable pressurized aerosols containing, most frequently, isoprenaline, and the downward trend in mortality is related to a reduction in the use of these aerosols and this drug (Inman and Adelstein, 1969 Diament, 1969a, 1969b; Palmer et al., 1970 placebo, indicating that both drugs increase pulse rate somewhat. There was no increase in systolic or diastolic blood pressure.
In Table II the mean change in the measurements is shown for the whole period of the trial. While the rise in the spirometric measurements was greater with salbutamol versus placebo than with terbutaline versus placebo the difference between salbutamol and terbutaline did not reach significant levels. There was a highly significant increase in pulse rate after both drugs. The apparent rise in systolic blood pressure after terbutaline is most likely due to the lower control readings before this drug compared with salbutamol and placebo. The incidence of side-effects is shown in Table III . Fine finger tremor was the most common, occurring in four patients after salbutamol and in five after terbutaline. Only one patient, however, experienced this side effect on both drugs. Two patients, one on each of the active drugs, complained of palpitation and one on terbutaline noted sweating.
Discussion
This trial shows that salbutamol and terbutaline are potent long-acting bronchodilator drugs when given orally. The reduction in airway obstruction as shown by the rise in FEV, appeared to be somewhat greater after 5 mg of salbutamol than after 5 mg of terbutaline. As the mean increase in FEV1 obta'ined during the whole period of the trial did not differ significantly as between salbutamol and terbutaline we consider they are probably equally active in the relief of asthmatic airway obstruction and that terbutaline may be used as a satisfactory alternative to salbutamol. Both drugs caused slight tachycardia but there was no change in systolic or diastolic blood pressure. The cardiac effects did not lead to a fall in Pao2, in fact it rose slightly after both drugs, though the rise was not statistically significant. There was no change in the level of alveolar ventilation and therefore in the PaCo2. Fine finger tremor was the commonest side effect occurring in about a third of the patients having either drug. This was usually not troublesome at rest but became evident during fine co-ordinated movements such as writing or sewing. As only one patient developed this symptom on both drugs it seems likely that where tremor occurs with one drug the other can be used as an alternative. Our clinical experience subsequent to the completion of this trial is that reducing the dose usually results in the disappearance or a noticeable reduction of the tremor without significantly reducing the bronchodilator effect. The dose used in the trial was 5 mg, the dose now recommended for salbutamol is 2-4 mg three times a day, so that in practice tremor should be an infrequent limiting factor to the use of these drugs.
